Clinical Trials Logo

Major Depressive Episode clinical trials

View clinical trials related to Major Depressive Episode.

Filter by:

NCT ID: NCT01944293 Completed - Bipolar Disorder Clinical Trials

Ketamine for Suicidality in Bipolar Depression

Start date: September 2013
Phase: Phase 1/Phase 2
Study type: Interventional

This study is designed to compare the effectiveness of two medications, Ketamine and Midazolam, for rapidly relieving suicidal thoughts in people suffering from bipolar depression. The first drug, ketamine, is an experimental antidepressant that early studies have shown may quickly reduce suicidal thoughts, but we are not sure how well it may work. Midazolam, the comparison drug, is not thought to reduce depression or suicidal thoughts.

NCT ID: NCT01869374 Completed - Depression Clinical Trials

Study Comparing Magnetic Seizure Therapy (MST) to Electroconvulsive Therapy (ECT) for Depression in Older Adults

MSTvsEST
Start date: August 2012
Phase: Phase 1/Phase 2
Study type: Interventional

To evaluate the feasibility, tolerability and efficacy of Magnetic Seizure Therapy (MST) in elderly patients with a major depressive episode, who are randomly assigned to receive an acute course of MST or ECT. The investigators hypothesize: 1. MST and ECT will have similar antidepressant efficacy 2. MST will have less post-treatment amnesia than ECT as reflected in a primary measures of anterograde and retrograde amnesia following the acute treatment phase. 3. At follow up, MST will show a lesser degree of persisting deficit in measures of retrograde amnesia than ECT.

NCT ID: NCT01620502 Completed - Clinical trials for Major Depressive Episode

N-3 Polyunsaturated Fatty Acids in the Prevention and Treatment for IFN-induced Depression

Start date: July 2009
Phase: N/A
Study type: Interventional

The first part is a double-blind placebo-controlled trial to identify the effects of omega-3 polyunsaturated fatty acids (PUFAs) in prevention of IFN-induced depression. The second part is a double-blind trial to identify the antidepressant effects of omega-3 PUFAs in patients with IFN-induced depression.

NCT ID: NCT01441505 Recruiting - Clinical trials for Major Depressive Episode

A Study of Ketamine as an Antidepressant

Start date: September 2011
Phase: Phase 2
Study type: Interventional

Recently, interest has emerged in the use of ketamine as an antidepressant. Recent placebo-controlled clinical trials administering a single dose and an open label trial giving repeated doses shown that ketamine is markedly superior to placebo at reducing depression, including in treatment-resistant patients, and that its antidepressant effects have a very rapid onset. This clinical study consists of two phases. In Phase I, participants who satisfy inclusion criteria will receive ketamine at variable doses (0.1mg/kg-0.5mg/kg) or a placebo (saline, or 0.01mg/kg midazolam) once a week over up to 6 weeks. If participants qualify for Phase II, they will receive repeated sessions of ketamine at variable doses over three weeks. During both phases, mood, psychiatric, and neuropsychological outcomes will be measured.

NCT ID: NCT01099592 Terminated - Clinical trials for Acute Coronary Syndrome

Antidepressants to Promote Recovery of Cardiac Patients Suffering From Depression

ARCADE
Start date: November 2010
Phase: Phase 4
Study type: Interventional

Depression is frequently seen in cardiac patients. It has been shown that depression often has a negative impact on the course of coronary disease. More recently, research has demonstrated that some antidepressants can be used safely to treat depressed coronary patients. Although the majority of patients improve substantially with antidepressant treatment, a significant proportion do not respond to antidepressants. This project seeks to better understand why depression does not improve equally well in all patients. Ultimately, the hope is to improve the treatments available to people affected by both cardiac disease and depression, and to help select the best type of treatment in advance for each individual based on his or her personal history, and biological characteristics.

NCT ID: NCT00998231 Completed - Clinical trials for Major Depressive Episode

Major Depression and Messenger RNAs

Start date: July 2009
Phase: N/A
Study type: Interventional

Major Depressive Episode (MDE) affects nearly 15% of the general population. In a preliminary study, the investigators identified 12 genes whose expression was either altered between patient and control samples and/or between first patient samples and samples from the same patients obtained 8 weeks later. However, this study did not assess evolution of these alterations beyond an 8-week window and only 2 time points were considered. The investigators aim to compare gene expression difference for 21 candidate genes, of which 12 were already investigated, in 2 groups of subjects. MDE and control samples will be analyzed across a large time window to draw a better picture of the complex progression during MDE.

NCT ID: NCT00852592 Completed - Bipolar Disorder Clinical Trials

Light Therapy for Bipolar Disorder. Efficacy of Light Therapy for Bipolar Depression: A Randomized Controlled Trial

Start date: May 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to understand the efficacy of light therapy for bipolar depression.

NCT ID: NCT00680433 Completed - Clinical trials for Major Depressive Episode

Ketamine as an Anaesthetic Agent in Electroconvulsive Therapy (ECT)

Start date: April 2008
Phase: Phase 4
Study type: Interventional

Research into the mechanisms underlying memory impairment in ECT suggests that its development may be prevented by the administration of certain medications at the time of ECT treatment. For example there are reasons to believe that ketamine, also used as an anaesthetic agent, may have such protective properties. In this clinical study patients undergoing a course of ECT will be offered the opportunity to receive a small dose of ketamine (or a placebo) as part of their anaesthetic at the time of ECT treatment. Mood changes and any memory changes will be evaluated to see if the subjects who received ketamine had less memory side effects than those who did not, while still improving their depression.

NCT ID: NCT00237666 Completed - Clinical trials for Major Depressive Episode

Open-Label Study of Geodon in Non-Rapid Cycling Bipolar II Patients With Major Depression

Start date: February 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the antidepressant effectiveness of Geodon for the treatment of patients diagnosed with Bipolar II disorder who are currently experiencing a major depressive episode.